Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
The CDMO upgrade represents a transformational step for Remedium Lifecare
EBITDA before special items decreases to €4.08 billion (7.4%)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Gelhaus has a proven track record of driving business growth
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Subscribe To Our Newsletter & Stay Updated